Glaukos submitted a new drug application to the FDA for Epioxa, an epithelium-on corneal cross-linking iLink therapy for the treatment of keratoconus, according to a company press release.
Epioxa is designed to enhance cross-linking by preserving the corneal epithelium, improving patient comfort and reducing both procedure and recovery time with its drug formulation that allows for penetration of the epithelial layer of the cornea, a stronger UV-A irradiation protocol and supplemental oxygen. The NDA is supported by data from two phase 3 trials, both of which demonstrated positive safety and